Deferasirox
Treatment for Thalassemias
Typical Dosage: 7-30 mg/kg once daily
Effectiveness
80%
Safety Score
65%
Clinical Trials
49
Participants
25K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
7-30 mg/kg once daily
Time to Effect
months to years for clinical benefits
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$4,000
Side Effect Mgmt:$1,000
Total Annual:$15,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$112,000/QALY
QALYs Gained
7
Outcome-Based Costs
Cost per Responder
$17,647
Comparison vs Deferoxamine
Cost Difference
+$5,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Risk Assessment
Requires Monitoring
YesNeeds lab work/checkups
Deferasirox Outcomes
for Thalassemias
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+85%
Common Side Effects
GI disturbances (nausea, vomiting, diarrhea, abdominal pain)
+15%
Skin rash
+7%
Increased serum creatinine
+3%
Increased liver transaminases
+3%
Headache
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
15 completed trials for Deferasirox in Thalassemias
Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation
NCT03637556COMPLETEDPHASE2
25 participants
INTERVENTIONAL
New York, United States +3 more
Started: Aug 20, 2019
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
NCT00171210COMPLETEDPHASE3
506 participants
INTERVENTIONAL
Los Angeles, United States +48 more
Started: Oct 1, 2004
Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox
NCT01905774COMPLETED
36 participants
OBSERVATIONAL
Afula, Israel
Started: Mar 1, 2011
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
NCT00447694COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Los Angeles, United States +2 more
Started: Feb 1, 2006
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
NCT00560820COMPLETEDPHASE1
11 participants
INTERVENTIONAL
Cagliari, Italy +2 more
Started: Sep 1, 2007
Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
NCT01709838COMPLETEDPHASE4
134 participants
INTERVENTIONAL
Nanning, China +10 more
Started: Dec 6, 2012
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
NCT00061750COMPLETEDPHASE3
595 participants
INTERVENTIONAL
Los Angeles, United States +6 more
Started: May 1, 2003
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
NCT01250951COMPLETEDPHASE4
111 participants
INTERVENTIONAL
Moscow, Russia +1 more
Started: Dec 1, 2009
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
NCT00564941COMPLETEDPHASE4
309 participants
INTERVENTIONAL
Budapest, Hungary +3 more
Started: Dec 1, 2007
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
NCT00171171COMPLETEDPHASE3
252 participants
INTERVENTIONAL
Cairo, Egypt +4 more
Started: May 1, 2004
Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec
NCT00879242COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Cagliari, Italy +1 more
Started: Feb 1, 2009
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
NCT00171301COMPLETEDPHASE4
233 participants
INTERVENTIONAL
Cairo, Egypt +4 more
Started: Jun 1, 2005
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
NCT00390858COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Lyon, France +3 more
Started: Sep 1, 2003
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
NCT00901199COMPLETEDPHASE2
22 participants
INTERVENTIONAL
Oakland, United States
Started: Sep 1, 2007
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
NCT00873041COMPLETEDPHASE2
166 participants
INTERVENTIONAL
Oakland, United States +20 more
Started: Nov 1, 2008
Showing 20 of 51 total trials